Press Releases Press Releases Year None2018201720162015 August 30, 2018 Surface Oncology to Present at the Baird 2018 Global Healthcare Conference Read More August 14, 2018 Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018 Read More July 30, 2018 FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma Read More June 21, 2018 Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal Read More June 12, 2018 Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 Read More June 11, 2018 Surface Oncology to be Added to the Russell 3000 Index and Russell 2000 Index Read More June 8, 2018 Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference Read More May 29, 2018 Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018 Read More May 15, 2018 Surface Oncology to Present at 2018 UBS Global Healthcare Conference Read More April 23, 2018 Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement Read More Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14 Print Page RSS Email Alerts Contact IR Search
Press Releases Year None2018201720162015 August 30, 2018 Surface Oncology to Present at the Baird 2018 Global Healthcare Conference Read More August 14, 2018 Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018 Read More July 30, 2018 FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma Read More June 21, 2018 Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal Read More June 12, 2018 Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 Read More June 11, 2018 Surface Oncology to be Added to the Russell 3000 Index and Russell 2000 Index Read More June 8, 2018 Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference Read More May 29, 2018 Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018 Read More May 15, 2018 Surface Oncology to Present at 2018 UBS Global Healthcare Conference Read More April 23, 2018 Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement Read More Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
August 14, 2018 Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018 Read More
July 30, 2018 FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma Read More
June 21, 2018 Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal Read More
June 12, 2018 Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 Read More
June 11, 2018 Surface Oncology to be Added to the Russell 3000 Index and Russell 2000 Index Read More
June 8, 2018 Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference Read More
May 29, 2018 Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018 Read More
April 23, 2018 Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement Read More
